Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Total
██.█% Sign up free to reveal

Cellebrite Di Ltd. (CLBT) AI Forecast

Our AI analyzed Cellebrite Di Ltd.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$CLBT Neutral Signal Full forecast available
Sign Up Free

Cellebrite Di Ltd. (CLBT) Stock Forecast Sept. 17, 2026

Cellebrite Di Ltd. (CLBT) AI Stock Price Forecast & Investment Analysis

Cellebrite Di Ltd. Stock Price Chart and Technical Analysis

Loading chart...

Cellebrite Di Ltd. (CLBT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Cellebrite Di Ltd.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 17, 2026, 9:26 p.m. (UTC)

Cellebrite Di Ltd. Investment Summary

When evaluating whether Cellebrite Di Ltd. (CLBT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Cellebrite Di Ltd. (CLBT) operates within the Technology sector, specifically in the Services-Prepackaged Software industry. . With a market capitalization of $3 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Cellebrite Di Ltd.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Cellebrite Di Ltd. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Cellebrite Di Ltd. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Cellebrite Di Ltd.

Sign Up Free
Corporate Identity

Cellebrite Di Ltd. (Stock Symbol: CLBT) is a prominent company operating within the Technology sector, with a specific focus on the Services-Prepackaged Software industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Cellebrite Di Ltd.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cellebrite Di Ltd....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Cellebrite Di Ltd....

Unlock Full Company Profile

Get complete details about Cellebrite Di Ltd.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Cellebrite Di Ltd....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Cellebrite Di Ltd....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Cellebrite Di Ltd....

Unlock Financial Analysis

Get complete financial metrics for Cellebrite Di Ltd.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Cellebrite Di Ltd.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Cellebrite Di Ltd. strategically competes in the highly dynamic Services-Prepackaged Software marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Cellebrite Di Ltd. operates within the fast-evolving technology sector where competitive dynamics are shaped by innovation cycles, platform economics, and network effects. Technology companies must continuously invest in R&D to maintain relevance, while also defending against disruption from startups and adjacent market entrants. Success in this sector often requires achieving critical scale or establishing defensible intellectual property positions.

Operational Efficiency
Margin & Pricing Power Analysis

The company maintains a 84.3% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of 14.1% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This healthy operating margin shows balanced investment in growth functions while maintaining reasonable profitability.

Financial Strength & Leverage

Current ratio of 1.56 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Cellebrite Di Ltd. (CLBT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cellebrite Di Ltd. stock analysis.

Deep dive into Cellebrite Di Ltd.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Cellebrite Di Ltd. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Cellebrite Di Ltd.:

P/B Ratio 5.89x
Market Cap $2.85B
EPS $-1.04
Book Value/Share $1.94
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Cellebrite Di Ltd. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Cellebrite Di Ltd.: An ROE of -42.3% indicates room for improvement in shareholder value creation.

ROE -42.3%
ROA -21.8%
ROIC 21.7%
Gross Margin 84.3%
Operating Margin 14.1%
Net Margin -23.3%
EBT Margin -21.1%
Tax Rate -10.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Cellebrite Di Ltd.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Cellebrite Di Ltd.: A current ratio of 1.56 shows adequate liquidity.

Current Ratio 1.56x
Quick Ratio 1.54x
D/E Ratio 0.94x
Financial Leverage 1.94x
Working Capital $206M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Cellebrite Di Ltd.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Cellebrite Di Ltd.:

Operating Cash Flow $306M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Cellebrite Di Ltd. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Cellebrite Di Ltd.:

Inventory Turnover 18.1x
Days Inventory 20 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Cellebrite Di Ltd.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Cellebrite Di Ltd.:

Income Statement
Operating Income $123M
Net Income -$204M
R&D Expense $212M
SG&A Expense $554M
Cost of Goods Sold $138M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 576%
Cash & Short-term Investments 124%
Total Liabilities 455%
Accounts Receivable 105%
Inventory 8%
Dividend & Shareholder Information
Shares Outstanding 249M
Growth Metrics (YoY)
Net Income Growth -23.3%
EPS Growth -9.1%

Latest Cellebrite Di Ltd. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Cellebrite Di Ltd. (CLBT) stock price and investment outlook.

📰 Loading...

Where CLBT sits on the market map

Explore the map →

Cellebrite Di Ltd. Competitors & Peer Analysis - Technology Sector

Comparative analysis of Cellebrite Di Ltd. against industry peers and competitors in the Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast (Total) Market Cap (USD M) P/E Ratio P/B Ratio
ADBE ██% $100.44B 13.9x 8.7x
ADSK ██% $46.04B 28.0x 13.6x
AEYE ██% $91M x 28.1x
AI ██% $1.73B x 1.6x
AIFF ██% $15M x 1.0x
AISP ██% $66M 2.5x x
AITX ██% N/A x x
ALAR ██% N/A x x
ALKT ██% $2.01B x 5.5x
ALRM ██% $2.66B 22.6x 3.1x
AMPL ██% $1.73B x 12.7x
AMST ██% $6M x 4.6x
APCX ██% $10M x x
API ██% $1.41B x 2.2x
APPF ██% $7.78B 49.4x 14.8x
APPN ██% $2.73B x x
ARQQ ██% $263M x x
ASAN ██% $2.31B x 22.2x
ASFT ██% $1M x x
ATDS ██% N/A x x
ATHR ██% $42M x 42.1x
AUID ██% N/A x x
AVPT ██% $2.86B 40.0x 6.6x
AWRE ██% $26M x 1.3x
BAND ██% $1.63B x 4.0x
BB ██% $4.65B 77.8x 6.2x
BBAI ██% $1.36B x 1.8x
BCAR ██% $236M 27.2x x
BILL ██% $4.18B x 1.2x
BKYI ██% $4M x 0.9x
BL ██% $1.64B 47.1x 5.2x
BLIN ██% N/A x x
BLKB ██% $2.03B 13.5x 30.4x
BLZE ██% $812M x 10.5x
BMR ██% $19M x 1.2x
BNZI ██% $6M x 0.5x
BOX ██% $4.76B 36.4x x
BRZE ██% $2.82B x x
BSY ██% $9.49B 32.7x 7.9x
CCC ██% $3.73B x 2.1x
CCLD ██% $89M 8.9x 5.1x
CCSI ██% $671M 7.1x 16.1x
CDNS ██% $77.20B 65.9x 11.8x
CERT ██% $1.24B x 1.3x
CGNT ██% $619M x 3.0x
CHKP ██% $14.54B x 5.0x
CLBT ██% $2.85B x 5.9x
CLOQ ██% $25M x x
CLPS ██% $30M x x
CMRC ██% $284M x 5.5x
COUR ██% $1.39B x 1.2x
CRM ██% $206.19B 21.3x 6.0x
CRNC ██% $355M x 2.1x
CRWD ██% $247.14B 4132.9x x
CRWV ██% $45.97B x 9.2x
CTGL ██% $9M x x
CVLT ██% $6.02B 88.1x 115.6x
CWAN ██% $7.24B x 3.5x
CXAI ██% $6M x x
CXM ██% $1.30B 56.1x 2.5x
CYAB ██% $5M x x
DBX ██% $8.52B 19.2x x
DCBO ██% $693M x x
DDD ██% $522M x 2.2x
DDOG ██% $82.87B 466.7x 19.0x
DH ██% $103M x 0.7x
DOMO ██% $181M x x
DPLS ██% N/A x x
DSGX ██% $6.80B x 4.2x
DSNY ██% $5M x 2.7x
DT ██% $15.95B 105.4x 6.5x
DTSS ██% N/A x x
DUOL ██% $6.93B 16.9x 4.9x
DUOT ██% N/A x x
EA ██% $52.84B 63.7x 7.5x
EBZT ██% N/A x x
EGAN ██% $141M 15.9x 1.7x
ESTC ██% $8.93B 23.8x 6.9x
EVCM ██% $1.40B 41.3x 2.0x
EXFY ██% $210M x 2.7x
FATN ██% $78M x 2.9x
FDCT ██% $10M x 0.3x
FDCTD ██% $7M 0.4x 0.2x
FIG ██% $12.29B x 8.3x
FNGR ██% $9M x 0.7x
FROG ██% $11.42B x 11.9x
FRSH ██% $3.32B 17.9x 3.7x
FRSX ██% $35M x 9.0x
FSLY ██% $3.75B x 3.8x
GDYN ██% $651M 227.3x 1.3x
GEG ██% $67M x 1.6x
GEN ██% $18.35B 17.4x 6.9x
GHST ██% $2M x x
GLBE ██% $6.24B x 6.7x
GMER ██% N/A x x
GNS ██% $24M x x
GRRR ██% N/A x x
GTIC ██% N/A x x
GTLB ██% $8.13B x 8.8x
GTM ██% $1.19B x 1.4x
GWRE ██% $12.03B 86.4x 10.1x
GXAI ██% $6M x 0.4x
HPAI ██% N/A x x
HUBS ██% $11.79B 80.3x 7.1x
IDAI ██% N/A x x
IDN ██% $48M 15.4x 2.1x
IFBD ██% $8M x 0.1x
IIIV ██% $387M 45.5x 1.4x
IMAA ██% $30K x x
INLX ██% N/A x x
INSE ██% $129M x x
INTA ██% $2.83B x 8.9x
ITOX ██% N/A x x
IVDA ██% $4M x 0.7x
KARO ██% N/A x x
KC ██% $42.20B x 4.5x
KLTR ██% $216M x 127.6x
KOAN ██% N/A x x
KVYO ██% $4.62B 680.5x 4.8x
LIVG ██% N/A x x
LPSN ██% $655M x x
LSPD ██% $1.41B x x
MANH ██% $12.36B 58.8x 78.5x
MAPS ██% N/A x x
MBLY ██% $1.97B x 0.1x
MCHX ██% N/A x x
MDB ██% $30.32B 514.7x 10.2x
MFON ██% $3M x x
MKLY ██% $250M 58.5x x
MNDY ██% $4.81B x 3.9x
MQ ██% $1.65B 159.3x 2.3x
MRDN ██% N/A x x
MSFT ██% $3.64T 27.2x 8.2x
MSGM ██% $20M 8.4x 5.1x
MYPS ██% $60M x 12.0x
MYSZ ██% N/A x x
NABL ██% $727M x 0.9x
NAVN ██% $5.87B x 4.5x
NCNO ██% $2.29B 60.2x 2.5x
NET ██% $115.60B x 71.4x
NICE ██% $6.37B x 1.6x
NOW ██% $146.06B x 11.7x
NTES ██% N/A x x
NTNX ██% $18.57B 67.3x x
NTSK ██% $7.06B x 45.1x
NTWK ██% $51M x 1.4x
NXNT ██% $11M x 5.0x
NYAX ██% $1.60B x x
OCTV ██% $4.90B x 1.0x
OKTA ██% $32.89B 111.1x 4.7x
OPRA ██% $1.65B x x
ORCL ██% $432.88B 22.9x 6.5x
PATH ██% $7.10B 19.6x 3.7x
PAYC ██% $10.26B 21.0x 18.0x
PCOR ██% $7.90B x 6.2x
PCTY ██% $7.82B 29.0x 6.4x
PD ██% $1.14B 6.2x 4.9x
PDFS ██% $1.77B 171.9x 4.8x
PDYN ██% $277M x 3.9x
PERF ██% N/A x x
PHGE ██% $3M x 0.3x
PLTR ██% $418.92B 138.9x 42.9x
PNXP ██% $30K x x
PRGS ██% $1.72B 19.3x 3.4x
PTC ██% $14.23B 11.6x 4.1x
QLYS ██% $6.33B 30.7x 11.3x
QTWO ██% $3.71B 40.4x 5.8x
QUBT ██% $1.81B x 1.1x
QXL ██% $111M x 4.3x
RBLX ██% $33.88B x 222.9x
RBRK ██% $21.76B x x
RCAT ██% N/A x x
RDVT ██% $1.24B 76.0x 11.2x
RPD ██% $840M 41.7x 4.3x
RPMT ██% $66M x x
RYET ██% N/A x x
S ██% $8.06B x 5.6x
SAGT ██% N/A x x
SAIL ██% $11.62B x 1.7x
SAP ██% N/A x x
SCDA ██% N/A x x
SEGG ██% N/A x x
SHOP ██% $167.21B 86.7x 13.2x
SKIL ██% $56M x x
SKKY ██% $22M x 24.9x
SKTG ██% $10M x x
SMSI ██% $16M x 0.9x
SNAL ██% $22M x 2.3x
SNPS ██% $72.53B 67.4x 2.3x
SOUN ██% $2.63B x x
SPSC ██% $2.90B 37.2x 3.1x
SPT ██% $683M x 3.0x
SSAC ██% N/A x x
SSNC ██% $18.90B 21.9x 2.9x
SSTI ██% $79M x 1.2x
SVAQ ██% N/A x x
SVCO ██% $220M x 2.6x
SVMB ██% N/A x x
SWMR ██% $299M x 9.6x
TAOP ██% N/A x x
TDC ██% $2.71B 5.9x 4.6x
TEAM ██% $48.17B x 45.5x
TENB ██% $4.01B 594.2x 20.2x
TTAN ██% $5.60B x x
TTWO ██% $39.60B x 11.0x
TWLO ██% $36.69B 31.9x 4.1x
TYL ██% $14.19B 43.7x 4.7x
UPLD ██% $12M x x
UPYY ██% N/A x x
VEEV ██% $42.89B 42.3x 5.8x
VERX ██% N/A x x
VII ██% N/A x x
VIIQ ██% N/A x x
VPRB ██% $8M 11.6x x
VRNS ██% $5.37B x 12.1x
VTEX ██% N/A x x
VWAV ██% $11M x 0.1x
WBSR ██% $10M x x
WEAV ██% $586M x 6.9x
WFCF ██% $65M 45.1x 7.4x
WHEN ██% N/A x x
WIMI ██% $14M x 0.0x
WK ██% $3.96B 84.1x x
XYZ ██% $46.04B 128.9x 2.1x
XZO ██% $1.48B 11.7x 5.1x
YAAS ██% N/A x x
YXT ██% N/A x x
ZDGE ██% $39M x x
ZETA ██% $15.49B x 16.7x
ZPTA ██% N/A x x
ZSPC ██% N/A x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Cellebrite Di Ltd. Stock Forecast

How accurate are Cellebrite Di Ltd. stock predictions?

Our AI model shows a 21% Spearman correlation coefficient for CLBT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Cellebrite Di Ltd. stock price forecasts?

Our analysis considers Cellebrite Di Ltd.'s financial metrics, Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Cellebrite Di Ltd. a good investment in 2026?

Based on our AI analysis, Cellebrite Di Ltd. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Cellebrite Di Ltd. forecasts updated?

Cellebrite Di Ltd. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Cellebrite Di Ltd.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...